Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort

Author:

Smith Muneerah,Abdesselem Houari B.,Mullins MichelleORCID,Tan Ti-Myen,Nel Andrew J. M.,Al-Nesf Maryam A. Y.,Bensmail Ilham,Majbour Nour K.,Vaikath Nishant N.,Naik Adviti,Ouararhni Khalid,Mohamed-Ali Vidya,Al-Maadheed MohammedORCID,Schell Darien T.,Baros-Steyl Seanantha S.ORCID,Anuar Nur D.ORCID,Ismail Nur H.,Morris Priscilla E.,Mamat Raja N. R.,Rosli Nurul S. M.,Anwar Arif,Ellan Kavithambigai,Zain Rozainanee M.,Burgers Wendy A.,Mayne Elizabeth S.,El-Agnaf Omar M. A.ORCID,Blackburn Jonathan M.ORCID

Abstract

The COVID-19 pandemic has affected all individuals across the globe in some way. Despite large numbers of reported seroprevalence studies, there remains a limited understanding of how the magnitude and epitope utilization of the humoral immune response to SARS-CoV-2 viral anti-gens varies within populations following natural infection. Here, we designed a quantitative, multi-epitope protein microarray comprising various nucleocapsid protein structural motifs, including two structural domains and three intrinsically disordered regions. Quantitative data from the microarray provided complete differentiation between cases and pre-pandemic controls (100% sensitivity and specificity) in a case-control cohort (n = 100). We then assessed the influence of disease severity, age, and ethnicity on the strength and breadth of the humoral response in a multi-ethnic cohort (n = 138). As expected, patients with severe disease showed significantly higher antibody titers and interestingly also had significantly broader epitope coverage. A significant increase in antibody titer and epitope coverage was observed with increasing age, in both mild and severe disease, which is promising for vaccine efficacy in older individuals. Additionally, we observed significant differences in the breadth and strength of the humoral immune response in relation to ethnicity, which may reflect differences in genetic and lifestyle factors. Furthermore, our data enabled localization of the immuno-dominant epitope to the C-terminal structural domain of the viral nucleocapsid protein in two independent cohorts. Overall, we have designed, validated, and tested an advanced serological assay that enables accurate quantitation of the humoral response post natural infection and that has revealed unexpected differences in the magnitude and epitope utilization within a population.

Funder

National Research Foundation South Africa

Hamad Medical Corporation

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Reference40 articles.

1. Rolling Updates on Coronavirus Disease (COVID-19)https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen

2. Human Saliva: Non-Invasive Fluid for Detecting Novel Coronavirus (2019-nCoV)

3. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

4. How Two Tests Can Help Contain COVID-19 and Revive the Economy;de Walque,2020

5. Coronavirus Disease (COVID-19) Outbreak Situationhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3